Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Oct 20;17(10):e0276313.
doi: 10.1371/journal.pone.0276313. eCollection 2022.

Association between XRCC3 p.Thr241Met polymorphism and risk of glioma: A systematic review and meta-analysis

Shing Cheng Tan  1 , Teck Yew Low  1 , Hafiz Muhammad Jafar Hussain  2 , Mohamad Ayub Khan Sharzehan  1 , Hilary Sito  1 , Hamed Kord-Varkaneh  3 , Md Asiful Islam  4
Affiliations
Meta-Analysis

Association between XRCC3 p.Thr241Met polymorphism and risk of glioma: A systematic review and meta-analysis

Shing Cheng Tan et al. PLoS One. .

Abstract

Background: The XRCC3 p.Thr241Met (rs861539) polymorphism has been extensively studied for its association with glioma risk, but results remain conflicting. Therefore, we performed a systematic review and meta-analysis to resolve this inconsistency.

Methods: Studies published up to June 10, 2022, were searched in PubMed, Web of Science, Scopus, VIP, Wanfang, and China National Knowledge Infrastructure databases and screened for eligibility. Then, the combined odds ratio (OR) of the included studies was estimated based on five genetic models, i.e., homozygous (Met/Met vs. Thr/Thr), heterozygous (Thr/Met vs. Thr/Thr), dominant (Thr/Met + Met/Met vs. Thr/Thr), recessive (Met/Met vs. Thr/Thr + Thr/Met) and allele (Met vs. Thr). The study protocol was preregistered at PROSPERO (registration number: CRD42021235704).

Results: Overall, our meta-analysis of 14 eligible studies involving 12,905 subjects showed that the p.Thr241Met polymorphism was significantly associated with increased glioma risk in both homozygous and recessive models (homozygous, OR = 1.381, 95% CI = 1.081-1.764, P = 0.010; recessive, OR = 1.305, 95% CI = 1.140-1.493, P<0.001). Subgroup analyses by ethnicity also revealed a statistically significant association under the two aforementioned genetic models, but only in the Asian population and not in Caucasians (P>0.05).

Conclusion: We demonstrated that the XRCC3 p.Thr241Met polymorphism is associated with an increased risk of glioma only in the homozygous and recessive models.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Fig 1
Fig 1. Flow diagram of study selection.
Fig 2
Fig 2. Forest plots of the association between XRCC3 p.Thr241Met polymorphism and glioma risk.
Fig 3
Fig 3
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genet. 2012;205: 613–621. doi: 10.1016/j.cancergen.2012.10.009 - DOI - PubMed
    1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359: 492–507. doi: 10.1056/NEJMra0708126 - DOI - PubMed
    1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109: 93–108. doi: 10.1007/s00401-005-0991-y - DOI - PubMed
    1. Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgård G, et al.. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. 2012;308: 1881–1888. doi: 10.1001/jama.2012.12807 - DOI - PubMed
    1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al.. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10: 459–466. doi: 10.1016/S1470-2045(09)70025-7 - DOI - PubMed

Publication types

Substances